Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann K Adams

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Hastings Center Report|July 22, 2014
The third-party notification dilemma. CommentaryAnn K Adams
The Lancet. Oncology|July 2, 2021
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialJawad Fares, Atique U Ahmed, Ilya V Ulasov, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Hastings Center Report|July 22, 2014
The third-party notification dilemma. CommentaryAnn K Adams
The Lancet. Oncology|July 2, 2021
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialJawad Fares, Atique U Ahmed, Ilya V Ulasov, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Pageof 1